Prescribing antiepileptic drugs: Should patients be switched on the basis of cost?

CNS Drugs

Volumn 18, Issue 10, 2004, Pages 617-628

  Jobst, Barbara C ^a,b   Holmes, Gregory L ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; DEPAKOTE ER; ETHOSUXIMIDE; ETIRACETAM; FELBAMATE; FOSPHENYTOIN SODIUM; GABAPENTIN; GENERIC DRUG; LAMOTRIGINE; LONG ACTING DRUG; OXCARBAZEPINE; PHENOBARBITAL; PHENYTEK; PHENYTOIN; PLACEBO; PRIMIDONE; TIAGABINE; TOPIRAMATE; VALPROATE SEMISODIUM; VALPROIC ACID; VIGABATRIN; ZONISAMIDE;

ANTICONVULSANT ACTIVITY; ANTICONVULSANT THERAPY; CANADA; CLINICAL PRACTICE; CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; DISEASE CONTROL; DRUG BIOAVAILABILITY; DRUG CHOICE; DRUG COST; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG SYNTHESIS; EPILEPSY; HEALTH CARE COST; HEALTH CARE SYSTEM; HUMAN; LONG TERM CARE; PORTUGAL; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; SEIZURE; SIDE EFFECT; UNITED KINGDOM; UNITED STATES;

ANTICONVULSANTS; COST-BENEFIT ANALYSIS; DRUG COSTS; EPILEPSY; HUMANS; PRESCRIPTIONS, DRUG;

EID: 4344592086     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200418100-00001     Document Type: Review

References (59)

1. Heaney DC, Sander JWAS. Ensuring appropriate care in epilepsy: an overview of epidemiological and cost of illness considerations. Dis Manag Health Outcomes 1998; 4: 303-13
2. Begley CE, Famulari M, Annegers JF, et al. The cost of epilepsy in the United States: an estimate from population-based clinical and survey data. Epilepsia 2000; 41 (3): 342-51
3. Cockerell OC, Hart YM, Sander JW, et al. The cost of epilepsy in the United Kingdom: an estimation based on the results of two population-based studies. Epilepsy Res 1994; 18 (3): 249-60
4. Berto P, Tinuper P, Viaggi S. Cost-of-illness of epilepsy in Italy: data from a multicentre observational study (Episcreen). Pharmacoeconomics 2000; 17 (2): 197-208
5. Boon P, D'Have M, Van Walleghem P, et al. Direct medical costs of refractory epilepsy incurred by three different treatment modalities: a prospective assessment. Epilepsia 2002; 43 (1): 96-102
6. British National Formulary [online]. Available from URL: http://www.bnf.org. [Accessed 2003 Sep]
7. Heaney DC, Shorvon SD, Sander JW, et al. Cost minimization analysis of antiepileptic drugs in newly diagnosed epilepsy in 12 European countries. Epilepsia 2000; 41 Suppl. 5: S37-44
8. Daranzi Y, Mikati M. Treatment-refractory epilepsy: an overview of treatment options and costs. Dis Manag Health Outcomes 1997; 2: 111-23
9. Begley CE, Annegers JF, Lairson DR, et al. Cost of epilepsy in the United States: a model based on incidence and prognosis. Epilepsia 1994; 35 (6): 1230-43
10. Maltoni S, Messori A. Lifetime cost-utility analysis of patients with refractory epilepsy treated with adjunctive topiramate therapy. Clin Drug Invest 2003; 23 (4): 225-32
11. Selai CE, Smith K, Trimble MR. Adjunctive therapy in epilepsy: a cost-effectiveness comparison of two AEDs. Seizure 1999; 8 (1): 8-13
12. van Hout B, Gagnon D, McNulty P, et al. The cost effectiveness of two antiepileptic therapies in the absence of direct comparative data. Pharmacoeconomics 2003; 21 (5): 315-26
13. Levy P. Economic evaluation of antiepileptic drug therapy: a methodologic review. Epilepsia 2002; 43 (5): 550-8
14. Weinstein MC, Siegel JE, Gold MR, et al. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA 1996; 276 (15): 1253-8
15. Shorvon SD. The epidemiology and treatment of chronic and refractory epilepsy. Epilepsia 1996; 37 Suppl. 2: S1-3
16. Nashef L, Fish DR, Garner S, et al. Sudden death in epilepsy: a study of incidence in a young cohort with epilepsy and learning difficulty. Epilepsia 1995; 36 (12): 1187-94
17. Sperling MR, Feldman H, Kinman J, et al. Seizure control and mortality in epilepsy. Ann Neurol 1999; 46 (1): 45-50
18. Wirrell EC, Camfield PR, Camfield CS, et al. Accidental injury is a serious risk in children with typical absence epilepsy. Arch Neurol 1996; 53 (9): 929-32
19. Jones MW. Consequences of epilepsy: why do we treat seizures? Can J Neurol Sci 1998; 25 (4): S24-6
20. Appelton R, Group MRPEI. Seizure-related injuries in children with newly diagnosed epilepsy. Epilepsia 2002; 43: 764-7
21. Baker GA, Nashef L, van Hout BA. Current issues in the management of epilepsy: the impact of frequent seizures on cost of illness, quality of life, and mortality. Epilepsia 1997; 38 Suppl. 1: S1-8
22. Baker G, Jacoby A, Buck D, et al. Quality of life of people with epilepsy: a European study. Epilepsia 1997; 38: 353-62
23. van Hout B, Gagnon D, Souetre E, et al. Relationship between seizure frequency and costs and quality of life of outpatients with partial epilepsy in France, Germany, and the United Kindgom. Epilepsia 1997; 38 (11): 1221-6
24. Bourgeois BF, Prensky AL, Palkes HS, et al. Intelligence in epilepsy: a prospective study in children. Ann Neurol 1983; 14 (4): 438-44
25. Helmstaedter C, Kurthen M, Lux S, et al. Chronic epilepsy and cognition: a longitudinal study in temporal lobe epilepsy. Ann Neurol 2003; 54 (4): 425-32
26. Hermann BP, Seidenberg M, Bell B. The neurodevelopmental impact of childhood onset temporal lobe epilepsy on brain structure and function and the risk of progressive cognitive effects. Prog Brain Res 2002; 135: 429-38
27. Mattson RH, Cramer JA, Collins JF, et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures. N Engl J Med 1985; 313 (3): 145-51
28. Mattson RH, Cramer JA, Collins JF. A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. The Department of Veterans Affairs Epilepsy Cooperative Study No. 264 Group. N Engl J Med 1992; 327 (11): 765-71
29. Navarro R, Ashraf T. Cost analysis of carbamazepine, phenytoin, and valproate for the use in complex partial seizures. Med Interface 1993; 6: 113-8
30. Brodie MJ, Richens A, Yuen AW. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Lancet 1995; 345 (8948): 476-9
31. Shakespeare A, Simeon G. Economic analysis of epilepsy treatment: a cost minimization analysis comparing carbamazepine and lamotrigine in the UK. Seizure 1998; 7: 119-25
32. Heaney DC, Shorvon SD, Sander JW. An economic appraisal of carbamazepine, lamotrigine, phenytoin and valproate as initial treatment in adults with newly diagnosed epilepsy. Epilepsia 1998; 39 Suppl. 3: S19-25
33. Lathers CM, Schraeder PL, Claycamp HG. Clinical pharmacology of topiramate versus lamotrigine versus phenobarbital: comparison of efficacy and side effects using odds ratios. J Clin Pharmacol 2003; 43 (5): 491-503
34. Vining EP, Mellitis ED, Dorsen MM, et al. Psychologic and behavioral effects of antiepileptic drugs in children: a double-blind comparison between phenobarbital and valproic acid. Pediatrics 1987; 80 (2): 165-74
35. Camfield CS, Chaplin S, Doyle AB, et al. Side effects of phenobarbital in toddlers; behavioral and cognitive aspects. J Pediatr 1979; 95 (3): 361-5
36. de Silva M, MacArdle B, McGowan M, et al. Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet 1996; 347 (9003): 709-13
37. Messori A, Trippoli S, Becagli P, et al. Adjunctive lamotrigine therapy in patients with refractory seizures: a lifetime cost-utility analysis. Eur J Clin Pharmacol 1998; 53 (6): 421-7
38. O'Neill B, Trimble M, Bloom D. Adjunctive therapy in epilepsy: a cost-effectiveness comparison of alternative treatment options. Seizure 1995; 4: 37-44
39. Hughes D, Cockerell OC. A cost minimization study comparing vigabatrin, lamotrigine and gabapentin for the treatment of intractable partial epilepsy. Seizure 1996; 5 (2): 89-95
40. Miller P, Millac P. Audit of the management of patients with refractory epilepsy. Seizure 1994; 3 (4): 295-9
41. McLachlan RS, Maher J. Management of antiepileptic drugs following epilepsy surgery: a review. Can J Neurol Sci 2000; 27 Suppl. 1: S106-10
42. Wilner AN. Physicians underestimate the frequency of generic carbamazepine substitution: results of a survey and review of the problem. Epilepsy Behav 2002; 3 (6): 522-5
43. Tyrer JH, Eadie MJ, Sutherland JM, et al. Outbreak of anticonvulsant intoxication in an Australian city. BMJ 1970; 4 (730): 271-3
44. Besag FM. Is generic prescribing acceptable in epilepsy? Drug Saf 2000; 23 (3): 173-82
45. Crawford P, Hall WW, Chappell B, et al. Generic prescribing for epilepsy: is it safe? Seizure 1996; 5 (1): 1-5
46. Rosenbaum DH, Rowan AJ, Tuchman L, et al. Comparative bioavailability of a generic phenytoin and Dilantin. Epilepsia 1994; 35 (3): 656-60
47. Chen SS, Allen J, Oxley J, et al. Comparative bioavailability of phenytoin from generic formulations in the United Kingdom. Epilepsia 1982; 23 (2): 149-52
48. Soryal I, Richens A. Bioavailability and dissolution of proprietary and generic formulations of phenytoin. J Neurol Neurosurg Psychiatry 1992; 55 (8): 688-91
49. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Assessment: generic substitution for antiepileptic medication. Neurology 1990; 40 (11): 1641-3
50. Welty TE, Pickering PR, Hale BC, et al. Loss of seizure control associated with generic substitution of carbamazepine. Ann Pharmacother 1992; 26 (6): 775-7
51. Revankar SN, Desai ND, Bhatt AD, et al. Comparison of absorption rate and bioavailability of two brands of carbamazepine. J Assoc Physicians India 1999; 47 (7): 699-702
52. Silpakit O, Amornpichetkoon M, Kaojarern S. Comparative study of bioavailability and clinical efficacy of carbamazepine in epileptic patients. Ann Pharmacother 1997; 31 (5): 548-52
53. Oles KS, Penry JK, Smith LD, et al. Therapeutic bioequivalency study of brand name versus generic carbamazepine. Neurology 1992; 42 (6): 1147-53
54. MacDonald JT. Breakthrough seizure following substitution of Depakene capsules (Abbott) with a generic product. Neurology 1987; 37 (12): 1885
55. Vadney VJ, Kraushaar KW. Effects of switching from Depakene to generic valproic acid on individuals with mental retardation. Ment Retard 1997; 35 (6): 468-72
56. Sherwood Brown E, Shellhorn E, Suppes T. Gastrointestinal side-effects after switch to generic valproic acid. Pharmacopsychiatry 1998; 31 (3): 114
57. DeToledo JC, Ramsay RE. Fosphenytoin and phenytoin in patients with status epilepticus: improved tolerability versus increased costs. Drug Saf 2000; 22 (6): 459-66
58. Marchetti A, Magar R, Fischer J, et al. A pharmacoeconomic evaluation of intravenous fosphenytoin (Cerebyx) versus intravenous phenytoin (Dilantin) in hospital emergency departments. Clin Ther 1996; 18 (5): 953-66
59. Touchette DR, Rhoney DH. Cost-minimization analysis of phenytoin and fosphenytoin in the emergency department. Pharmacotherapy 2000; 20 (8): 908-16